BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Yartemlea (narsoplimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Yartemlea (narsoplimab)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04488081-10906@assetmemo.bio
DTSTAMP:20261121T005610Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Yartemlea (narsoplimab): Phase 2 readout est. (NCT04488081)
DESCRIPTION:Yartemlea (narsoplimab)\, phase 2.\nStudy: I-SPY COVID-19 TRIAL
 : An Adaptive Platform Trial for Critically Ill Patients\nEstimated primar
 y completion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/narsoplimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04488081
URL:https://assetmemo.bio/drug/narsoplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
